Department of Environmental Biotechnology, Bharathidasan University, Tiruchirappalli 620 024, Tamil Nadu, India.
FEBS Lett. 2013 Jan 16;587(2):105-10. doi: 10.1016/j.febslet.2012.11.019. Epub 2012 Dec 7.
Doxorubicin-treated animals show elevated serum triglyceride and blood glucose levels. Adipocytes play an important role in buffering blood glucose and lipids. A raise in serum lipid level triggers adipogenesis in order to increase the lipid absorption capacity of adipose tissue. Doxorubicin inhibits adipogenesis through the down-regulation of PPARγ, a crucial component of the lipid metabolic pathway which controls the expression of glucose and fatty acid transporters. Doxorubicin-mediated down-regulation of PPARγ inhibits blood glucose and lipid clearance thereby causing hyperglycemia and hyperlipidemia resulting in lipotoxicity, glucotoxicity, inflammation and insulin resistance. Therefore we hypothesize that doxorubicin treatment could mimic a type 2 diabetic condition.
多柔比星处理的动物表现出血清甘油三酯和血糖水平升高。脂肪细胞在缓冲血糖和脂质方面起着重要作用。血清脂质水平的升高会触发脂肪生成，以增加脂肪组织的脂质吸收能力。多柔比星通过下调关键脂质代谢途径的组成部分 PPARγ 来抑制脂肪生成，该途径控制葡萄糖和脂肪酸转运蛋白的表达。多柔比星介导的 PPARγ 下调抑制血糖和脂质清除，从而导致高血糖和高血脂，导致脂肪毒性、糖毒性、炎症和胰岛素抵抗。因此，我们假设多柔比星治疗可以模拟 2 型糖尿病的情况。
